IGF-1 DES

IGF-1 DES: Localized Muscle Growth Peptide

IGF-1 DES (also known as des(1–3)IGF-1) is a truncated 67-amino-acid analog of insulin-like growth factor-1 with reduced IGF-binding protein (IGFBP) affinity due to deletion of the N-terminal Gly-Pro-Glu tripeptide [1]. Licensed practitioners interested to buy IGF-1 DES can contact Medical Spa Rx’s professional support team for guidance on sourcing from qualified suppliers and for access to supporting documentation, including purity information. This page provides an overview of IGF-1 DES and its research applications through the sections and FAQ below.

IGF-1 DES & Localized Muscle Growth: Mechanism & Structural Overview

IGF-1 DES is a truncated analog of insulin-like growth factor-1. Native IGF-1 contains 70 amino acids; IGF-1 DES contains 67, produced by deletion of the N-terminal Gly-Pro-Glu tripeptide [1]. That structural change reduces its affinity for IGF-binding proteins [1], limiting plasma sequestration and concentrating free peptide activity near the injection site. The result is a short plasma half-life of approximately 20–30 minutes, direct IGF-1 receptor binding, and downstream PI3K/Akt/mTOR signaling that supports satellite cell activation and protein synthesis in the target tissue [1][2].

This localized activity profile distinguishes IGF-1 DES from longer-acting IGF-1 analogs and upstream GH secretagogues. It does not stimulate pituitary GH release or increase hepatic IGF-1 production. Its research rationale is specific: acute IGF-1 receptor activation concentrated at a defined muscle group.

IGF-1 DES is considered by sports medicine physicians, anti-aging clinicians, and compounding pharmacists when a protocol calls for site-specific IGF-1 receptor activity rather than broad systemic stimulation. It is not FDA-approved and is classified as a research compound only.

IGF-1 DES vs LR3: Difference Between IGF-1 LR3 and IGF DES

IGF-1 DES and IGF-1 LR3 are both IGF-1 analogs, but they are not interchangeable.

IGF-1 LR3 is an 83-amino-acid analog that retains the native IGF-1 sequence, adds a 13-amino-acid N-terminal extension, and substitutes Arg3 for Glu3. These modifications reduce IGFBP binding and extend the activity window considerably, with a half-life commonly reported at roughly 20–30 hours. (Note: exact human half-life values for IGF-1 LR3 are not well-established in peer-reviewed literature; most data derive from animal models.) IGF-1 LR3 is designed for sustained systemic exposure and is more appropriate for whole-body IGF-1R exposure models.

IGF-1 DES removes the first three N-terminal amino acids from native IGF-1, which also reduces IGFBP binding but produces a much shorter activity window of approximately 20–30 minutes. This makes IGF-1 DES more transient and better suited to site-focused receptor activity. In practical terms: LR3 for systemic IGF-1R support across multiple tissue groups; DES for targeted, localized IGF-1 receptor activation in a defined muscle. Practitioners may use each at different protocol phases depending on the research objective.

How to Inject IGF-1 DES: Dosage, Timing, & Storage

Route of administration is central to IGF-1 DES’s research rationale. Published protocols describe intramuscular (IM) injection directly into the target muscle group. Subcutaneous administration bypasses the localization mechanism and is not considered equivalent.

Administration – Practitioner-Reported Only; No FDA-Validated Protocol

• Route: Intramuscular injection into the target muscle; subcutaneous is not a substitute
• Dose: 20–100 mcg per injection site (practitioner-reported range). No RCT dose-optimization studies exist. Doses above 100 mcg per site may increase hypoglycemia risk without demonstrated benefit.
• Frequency: Once daily or 2–3 times weekly (practitioner-reported). IGF-1 DES half-life is approximately 20–30 minutes [1], making timing relative to training theoretically relevant but not clinically validated.
• Timing: Administered close to the post-exercise window (practitioner-reported). Local receptor and satellite cell activity may be heightened post-training, but this has not been confirmed in human IGF-1 DES studies.
• Reconstitution: Bacteriostatic water, per standard peptide handling
• Storage: 2–8°C post-reconstitution; protect from light; use within 24–48 hours; discard after 48 hours

Note: All dosing information above is practitioner-reported only. No clinical trial data support human use. Institutional review board (IRB) approval is required for any human research protocol.

IGF-1 DES Benefits, Side Effects, and Legal Status

IGF-1 DES is discussed in three research contexts. Evidence quality varies significantly by application:

• Localized hypertrophy (mechanistically plausible; preclinical only): Reduced IGFBP binding and direct IGF-1R activation near the target tissue may support satellite cell activation and protein synthesis via PI3K/Akt/mTOR signaling [2]. No controlled human clinical trials exist for IGF-1 DES-induced hypertrophy.
• Performance recovery (preclinical only): The rationale draws on IGF-1R signaling in muscle repair and post-training tissue remodeling from animal models. No controlled human data specific to IGF-1 DES are available.
• Fat oxidation (speculative): Extrapolated from general IGF-1 biology on lipid metabolism. No IGF-1 DES-specific human data exist on fat metabolism.

Safety Considerations

• Hypoglycemia (documented risk): IGF-1R activation produces insulin-like, glucose-lowering effects [2], particularly in fasted states or around the post-workout window. Required monitoring includes blood glucose before and approximately 30 minutes post-injection. Avoid use in research subjects with uncontrolled diabetes or those on insulin or sulfonylureas without a glucose monitoring protocol in place.
• Injection site reactions (reported): Redness, swelling, tenderness, and transient discomfort. Typically mild.
• Localized tissue overgrowth (theoretical): Chronic high-dose use concentrated in a single area poses a theoretical proliferative risk. Long-term human safety data for IGF-1 DES are absent, and no formal characterization of proliferative risk exists.
• Other contraindications: Use is contraindicated in active malignancy, as IGF-1R activation may promote cell proliferation. Contraindicated in pregnancy and lactation. Additive hypoglycemia risk exists with concurrent insulin, sulfonylurea, or metformin use.

Current Regulatory and Legal Status

• United States: Not FDA-approved for any indication; not listed on the FDA 503A bulk substances list. Research compound only.
• Australia: Not TGA-approved.
• WADA: IGF-1 and its analogs, including DES variants, are prohibited at all times — both in- and out-of-competition — under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) [3]. Licensed professionals working with competitive athletes should communicate this restriction clearly.

All regulatory details are subject to change. Verify current status within the relevant jurisdiction before any protocol consideration.

IGF-1 DES vs CJC-1295 & IGF-1 DES vs Ipamorelin

IGF-1 DES and CJC-1295 act at different points in the GH/IGF-1 axis. IGF-1 DES works downstream, binding directly to IGF-1 receptors in the target muscle and generating a short-lived, localized IGF-1R signal without depending on pituitary GH release or hepatic IGF-1 production. CJC-1295, particularly the DAC-modified form, works upstream as a GHRH analog that promotes sustained systemic GH release and broader IGF-1 elevation across multiple tissues. Practitioners looking to buy CJC-1295 for GH-axis optimization protocols will find it addresses a fundamentally different intervention point than IGF-1 DES. The latter is the more specific option when the protocol requires concentrated IGF-1R activity in a defined muscle group rather than systemic axis support.

Ipamorelin is also an upstream secretagogue, but it acts through GHS-R signaling rather than the GHRH receptor [4], stimulating pulsatile GH release with minimal reported cortisol or prolactin elevation [4]. It supports systemic GH/IGF-1 activity through the body’s own axis. IGF-1 DES acts further downstream at the IGF-1 receptor level, independent of GHS-R activation or endogenous GH release. Practitioners who buy Ipamorelin for clean GH-axis stimulation protocols will find IGF-1 DES serves a different purpose: it is more appropriate when the protocol calls for concentrated, site-specific IGF-1R activity rather than systemic GH support. The two compounds are not competing; depending on the research design, they may be considered alongside one another.

Where Can Practitioners Buy IGF-1 DES Online?

IGF-1 DES is available for research purposes to qualified licensed professionals only. When buying online, practitioners should source exclusively from suppliers with verifiable purity documentation, including a certificate of analysis (COA), LOT number traceability, and clear handling and storage specifications. Those looking to check for wholesale buying options should confirm that any supplier meets these documentation standards before proceeding.

Medical Spa Rx’s professional support team offers sourcing guidance and access to supporting documentation for licensed practitioners evaluating research-grade IGF-1 DES. For guidance on supplier qualification, purity records, and compliance considerations, contact the professional support team directly.

FAQs

1. What is IGF-1 DES?

IGF-1 DES is a 67-amino-acid truncated analog of insulin-like growth factor-1. The DES designation refers to the deletion of the N-terminal Gly-Pro-Glu tripeptide, which reduces IGFBP binding and supports short-lived, localized IGF-1 receptor activity at the injection site [1]. It is not FDA-approved and is classified as a research compound only.

2. What is the difference between IGF-1 DES and IGF-1 LR3?

IGF-1 DES has a short half-life of approximately 20–30 minutes and is associated with localized, site-specific IGF-1 receptor activation. IGF-1 LR3 has an extended half-life of roughly 20–30 hours and is designed for broader systemic IGF-1R exposure. DES is discussed in the context of targeted, localized hypertrophy research; LR3 is more appropriate for whole-body IGF-1R exposure models.

3. How do you inject IGF-1 DES?

Published protocols describe intramuscular injection into the target muscle group. Localization is central to the compound’s research rationale, and subcutaneous administration is not considered equivalent. Timing, route, and handling should be reviewed against available documentation and applicable regulatory requirements. No FDA-validated dosing protocol exists.

4. What is the theoretical rationale for IGF-1 DES timing?

Timing post-exercise is hypothesized to be relevant based on animal models showing heightened IGF-1R and satellite cell activity after resistance training. This has not been confirmed in human IGF-1 DES studies. The injection site determines where IGF-1R activation is concentrated. No clinical trial data support specific timing protocols. All protocol decisions require professional assessment and IRB approval for human research.

5. What are the side effects of IGF-1 DES?

Reported and theoretical concerns include hypoglycemia, injection site reactions, and localized tissue overgrowth with chronic high-dose use. IGF-1 DES is contraindicated in active malignancy and pregnancy. Human safety data are limited, and long-term proliferative risk has not been formally characterized. Glucose monitoring is a required consideration in any protocol discussion [2].

6. Is IGF-1 DES legal?

IGF-1 DES is not FDA-approved for any indication and is not listed on the 503A compounding list. WADA prohibits IGF-1 and its analogs, including DES variants, at all times — both in- and out-of-competition — under S2 [3]. Regulatory status should be verified by jurisdiction before any protocol consideration. (Current as of June 2026.)

7. Where can practitioners buy IGF-1 DES?

Practitioners evaluating where to buy IGF-1 DES wholesale should review supplier qualification, purity documentation, and applicable regulatory status. Medical Spa Rx’s professional support team can provide guidance on sourcing from qualified suppliers and access to supporting documentation, including certificates of analysis.

Sources

1. Ballard FJ, Wallace JC, Francis GL, Read LC, Tomas FM. Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. Int J Biochem Cell Biol. 1996;28(10):1085-1087. doi:10.1016/1357-2725(96)00056-8
2. Yoshida T, Delafontaine P. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells. 2020;9(9):1970. Published 2020 Aug 26. doi:10.3390/cells9091970
3. United States Anti-Doping Agency. IGF-1 and the World Anti-Doping Agency Prohibited List. Published April 7, 2014. https://www.usada.org/spirit-of-sport/igf-1-and-the-world-anti-doping-agency-prohibited-list/
4. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:1530/eje.0.1390552

The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice.